Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Inactivation of the mitogen-activated protein kinase pathway as a potential target-based therapy in ovarian serous tumors with KRAS or BRAF mutations.

Cancer research - 1 Mar 2005

Pohl Gudrun, Ho Chung-Liang, Kurman Robert J, Bristow Robert, Wang Tian-Li, Shih Ie-Ming

Abstract excerpt

Activation of mitogen-activated protein kinase (MAPK) occurs in response to various growth stimulating signals and as a result of activating mutations of the upstream regulators, KRAS and BRAF, which can be found in many types of human cancer. To investigate the roles of MAPK activation in tumors harboring KRAS or BRAF mutations, we inactivated MAPK in ovarian tumor cells using CI-1040, a compound that...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Benzamides
Share to Calcium-Calmodulin-Dependent Protein Kinases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cell Cycle

Share to Cyclin D1

Share to Cystadenocarcinoma, Serous

Share to Genes, ras

Share to Mitogen-Activated Protein Kinases

Share to Ovarian Neoplasms

Source

Identifiers

PMID: 15753399
DOI: 10.1158/0008-5472.CAN-04-3625

Genes

BRAF
KRAS

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Inactivation of the mitogen-activated protein kinase pathway as a potential target-based therapy in ovarian serous tumors with KRAS or BRAF mutations.PMID 15753399Read ↗

KRAS or BRAF mutation status is a useful predictor of sensitivity to MEK inhibition in ovarian cancer.Semantic proximity Read ↗

MAPK inhibition in BRAFV600E CRC.Semantic proximity Read ↗

Smad4 Inactivation Promotes Malignancy and Drug Resistance of Colon CancerSemantic proximity Read ↗

Sorafenib induces growth suppression in mouse models of gastrointestinal stromal tumor.Semantic proximity Read ↗

MAP4K4 and cancer: ready for the main stage?Semantic proximity Read ↗

MAP3K1 and MAP2K4 mutations are associated with sensitivity to MEK inhibitors in multiple cancer modelsSemantic proximity Read ↗

BRAF V600E-induced distinct DNA damage response defines the therapeutic potential of p53 activation for TP53 wild-type colorectal cancer.Semantic proximity Read ↗

Human mitogen-activated protein kinase kinase 4 as a candidate tumor suppressor.Semantic proximity Read ↗

Characterization of active mitogen-activated protein kinase in ovarian serous carcinomas.Semantic proximity Read ↗

Protein phosphatase 6 activates NF-κB to confer sensitivity to MAPK pathway inhibitors in KRAS- and BRAF-mutant cancer cells.Semantic proximity Read ↗

Analysis of the mitogen-activated protein kinase kinase 4 (MAP2K4) tumor suppressor gene in ovarian cancer.Semantic proximity Read ↗

A Role for K-ras in Conferring Resistance to the MEK Inhibitor, CI-1040Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.